A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Sep 2018

At a glance

  • Drugs Atezolizumab (Primary) ; Daratumumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms CALLISTO; DARZALEX
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 05 Sep 2018 Trial has been completed in Poland.
    • 17 Aug 2018 Planned End Date changed from 14 Oct 2019 to 22 Apr 2019.
    • 26 May 2018 Status changed from recruiting to discontinued, as reported in the Genmab media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top